Document is current
Any future updates will be listed below
-
Authors
Schissel, Carly K.
Mohapatra, Somesh http://orcid.org/0000-0001-9498-3834
Wolfe, Justin M.
Fadzen, Colin M.
Bellovoda, Kamela
Wu, Chia-Ling
Wood, Jenna A.
Malmberg, Annika B.
Loas, Andrei
Gómez-Bombarelli, Rafael http://orcid.org/0000-0002-9495-8599
Pentelute, Bradley L. http://orcid.org/0000-0002-7242-801X
-
Funding
Funding for this research was provided by:
National Science Foundation (4000057398)
Abdul Latif Jameel Clinic for Machine Learning in Health
MIT-SenseTime Alliance on Artificial Intelligence
Sarepta Therapeutics
- License Information
-
More Information
Article History
Received: 26 June 2020
Accepted: 5 July 2021
First Online: 9 August 2021
Competing interests
: B.L.P. is a co-founder of Amide Technologies and of Resolute Bio. Both companies focus on the development of protein and peptide therapeutics. The following authors are inventors on patents and patent applications related to the technology described: J.M.W., C.M.F. and B.L.P are co-inventors on patents WO 2020028254A1 (6 February 2020), WO2019178479A1 (19 September 2019), WO2019079386A1 (25 April 2019) and WO2019079367A1 (24 April 2019), which describe trimeric peptides for antisense delivery, chimeric peptides for antisense delivery, CPPs for antisense delivery and bicyclic peptide oligonucleotide conjugates, respectively. A.B.M., K.B., C.-L.W. and J.A.W. are employees of Sarepta Therapeutics, and Sarepta Therapeutics provided a portion of the funding for the work.
